Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials

Ítems similars

• Rosiglitazone RECORD study: glucose control outcomes at 18 months
  per: Home, P D, et al.
  Publicat: (2007)
• Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
  per: Komajda, Michel, et al.
  Publicat: (2010)
• Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
  per: MacDonald, Michael R., et al.
  Publicat: (2011)
• Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
  per: Komajda, Michel, et al.
  Publicat: (2008)
• Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT)
  per: Kahn, Steven E., et al.
  Publicat: (2010)